GMAB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Genmab A/S (GMAB) is not a strong buy for a beginner, long-term investor at this time. While the company has promising catalysts for 2026 and strong analyst support, the current technical indicators are mixed, and there are no immediate proprietary trading signals or significant financial data to support an entry now. The investor may consider monitoring the stock for better entry points or further developments in its clinical pipeline.
The MACD is positive and expanding, indicating bullish momentum. However, the RSI is neutral at 53.788, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5), suggesting a lack of strong upward momentum. Key support is at 24.302, and resistance is at 25.594. Overall, the technical indicators are mixed.
Genmab's epcoritamab showed a 67% overall response rate in clinical trials for elderly patients with diffuse large B-cell lymphoma.
Analysts highlight a 'catalyst-rich' 2026, with potential $5B+ peak sales from key assets like Epkinly, Rina-S, and petosemtamab.
Hedge funds and insiders are neutral, with no significant selling pressure.
The stock is underperforming in the regular and post-market sessions, with a -0.47% and -1.03% decline, respectively.
Moving averages are bearish, and the stock is trading below key resistance levels.
Analysts have lowered price targets recently, reflecting cautious optimism.
No financial data available for the latest quarter. Unable to assess growth trends or profitability.
Analysts are generally positive on Genmab, with multiple Buy ratings and price targets ranging from $30.50 to $40. However, recent price target reductions (e.g., Truist from $48 to $40, Morgan Stanley from $34 to $33) indicate tempered expectations. Analysts are optimistic about the company's pipeline and long-term growth potential despite challenges like the Darzalex royalty stream expiration in 2029.
